<- Go Home
Bayer Aktiengesellschaft
Bayer Aktiengesellschaft operates as a life science company in Europe, the Middle East, Africa, Germany, Switzerland, North America, the United States, the Asia Pacific, China, Latin America, and Brazil. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment offers nonprescription over-the-counter medicines for self-medication and self-care; nutritional supplements; allergy, cough, and cold; dermatology; pain and cardiovascular risk prevention; and digestive health products. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solutions, and pest and weed management products, as well as customer services for agriculture. It also engages in the breeding, propagation, and production/processing of seeds, including seed dressing. The company distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. Bayer Aktiengesellschaft was founded in 1863 and is based in Leverkusen, Germany.
Market Cap
EUR 36.9B
Volume
3.4M
Cash and Equivalents
EUR 6.7B
EBITDA
EUR 8.9B
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
EUR 27.0B
Profit Margin
59.35%
52 Week High
EUR 49.78
52 Week Low
EUR 18.38
Dividend
0.29%
Price / Book Value
1.42
Price / Earnings
-10.20
Price / Tangible Book Value
-1.62
Enterprise Value
EUR 66.8B
Enterprise Value / EBITDA
7.31
Operating Income
EUR 5.1B
Return on Equity
12.37%
Return on Assets
2.97
Cash and Short Term Investments
EUR 7.9B
Debt
EUR 37.6B
Equity
EUR 26.1B
Revenue
EUR 45.6B
Unlevered FCF
EUR 9.7B
Sector
Pharmaceuticals
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium